Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer.
about
Neuroendocrine differentiation in prostate cancerLoss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapseNear infrared photonic finger imager for prostate cancer screening.Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumorsNeuroendocrine differentiation in the progression of prostate cancer.Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors.Neuroendocrine differentiation of prostate cancer: a review.miR-145 suppress the androgen receptor in prostate cancer cells and correlates to prostate cancer prognosis.miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients.Somatostatin receptors over-expression in castration resistant prostate cancer detected by PET/CT: preliminary report of in six patients.Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma.Immunohistochemical expression and localization of somatostatin receptor subtypes in prostate cancer with neuroendocrine differentiation.Octreotide scintigraphy and Chromogranin A do not predict clinical response in patients with octreotide acetate-treated hormone-refractory prostate cancer.Expression of somatostatin and its receptor 1-5 in endometriotic tissues and cells
P2860
Q24657547-D0F57D8C-6B43-4776-AA6E-850D2B511BBAQ28540624-E7B4E752-18DB-4CBD-A43F-66CC3984ABADQ34069799-78981E44-4742-4B6D-884C-06C30ECFD2F6Q36322884-493DA531-6161-4C7D-9178-1EFDA7261D61Q37361501-3A991277-B07C-4C05-B129-438A8140E533Q37898112-EDDC679C-EBC0-4FB3-A17E-C179A48BFAC6Q38326554-32D6954D-9D66-4087-94C0-64B16F5F50BCQ38875539-1D970466-0EA3-4B6B-ADAC-A1EA080E37FEQ39168818-39CF864E-9AC8-4F55-ABB0-96A47F9043ADQ41558340-A7413C65-A5C1-4FFF-8EFA-7B4FC82365AEQ41828518-A818C0AD-4EB0-41C9-9D30-27BD63D1E962Q42474654-298BD44E-5AD5-47E6-AC4A-63ED88BC85DAQ46757943-F71B1081-B01D-495F-A506-F327CC1CFD63Q58552314-431CE7FE-1D17-4291-8491-54CA00731BC1
P2860
Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Expression of somatostatin rec ...... erplasia and prostatic cancer.
@en
Expression of somatostatin rec ...... erplasia and prostatic cancer.
@nl
type
label
Expression of somatostatin rec ...... erplasia and prostatic cancer.
@en
Expression of somatostatin rec ...... erplasia and prostatic cancer.
@nl
prefLabel
Expression of somatostatin rec ...... erplasia and prostatic cancer.
@en
Expression of somatostatin rec ...... erplasia and prostatic cancer.
@nl
P2093
P2860
P356
P1433
P1476
Expression of somatostatin rec ...... erplasia and prostatic cancer.
@en
P2093
Anders Bjartell
Jens Hansson
Nishtman Dizeyi
Per-Anders Abrahamsson
Virgil Gadaleanu
P2860
P356
10.1002/PROS.10121
P577
2002-09-01T00:00:00Z